Key Insights
If you want to know who really controls ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541), then you’ll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are retail investors with 32% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
While the holdings of retail investors took a hit after last week’s 11% price drop, institutions with their 21% holdings also suffered.
Let’s delve deeper into each type of owner of ImmuneOnco Biopharmaceuticals (Shanghai), beginning with the chart below.
View our latest analysis for ImmuneOnco Biopharmaceuticals (Shanghai)
What Does The Institutional Ownership Tell Us About ImmuneOnco Biopharmaceuticals (Shanghai)?
Institutional investors commonly compare their own returns to the returns of a commonly…
